Japan's Nichi-Iko snaps up Sagent for $736M to grow into top global generics firm


Tokyo-based Nichi-Iko Pharmaceutical will buy Sagent Pharmaceuticals ($SGNT) in a $736 million all-cash deal with management and boards from both sides agreeing to terms aimed at creating a global generics powerhouse.

Nichi-Iko will pay $21.75 for each share of Schaumburg, Illinois-based Sagent, a premium a tad over 40% to the share close price on Friday, July 8 of $15.50, Sagent said in a release on Monday. The transaction is slated to close in the second quarter of the Japanese company's financial year, which started April 1.

The purchase vaults Nichi-Iko out of its sole reliance on the Japanese market, potentially aiding sales in the key U.S. market and wider.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

"The transaction enhances Nichi-Iko's platform in the U.S. market to commercialize its biosimilar product pipeline and increase its presence in injectables," according to the press release.

"Through the acquisition, Nichi-Iko will raise its profile in the domestic and international generics market and advance the company's goal of becoming a top 10 global leader in generics."

Nichi-Iko's CEO noted the reach into the U.S. would not include any immediate changes in management and that the transaction was akin to a partnership.

“The U.S. market is a top priority for Nichi-Iko and we believe Sagent is an ideal partner to accelerate our international growth strategy," Yuchi Tamura, CEO for Nichi-Iko said in a statement.

- here's the release from Nichi-Iko (Japanese language)
- and one from Sagent
- and a story from Bloomberg

Related Articles:
Japanese firms eye sale of patent-expired drugs to fund new blockbusters


Suggested Articles

Novartis is doing more portfolio pruning, offloading three endocrine drugs to Recordati.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.